JP2002506818A - スタチン−マトリックスメタロプロテイナーゼ阻害剤組み合わせ物 - Google Patents

スタチン−マトリックスメタロプロテイナーゼ阻害剤組み合わせ物

Info

Publication number
JP2002506818A
JP2002506818A JP2000536378A JP2000536378A JP2002506818A JP 2002506818 A JP2002506818 A JP 2002506818A JP 2000536378 A JP2000536378 A JP 2000536378A JP 2000536378 A JP2000536378 A JP 2000536378A JP 2002506818 A JP2002506818 A JP 2002506818A
Authority
JP
Japan
Prior art keywords
acid
methyl
phenyl
ethyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000536378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002506818A5 (cg-RX-API-DMAC7.html
Inventor
ロジャー・スコウフィールド・ニュートン
ブルース・デイヴィッド・ロス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of JP2002506818A publication Critical patent/JP2002506818A/ja
Publication of JP2002506818A5 publication Critical patent/JP2002506818A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000536378A 1998-03-17 1998-11-20 スタチン−マトリックスメタロプロテイナーゼ阻害剤組み合わせ物 Pending JP2002506818A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17
US60/078,265 1998-03-17
PCT/US1998/024681 WO1999047138A1 (en) 1998-03-17 1998-11-20 Statin-matrix metalloproteinase inhibitor combinations

Publications (2)

Publication Number Publication Date
JP2002506818A true JP2002506818A (ja) 2002-03-05
JP2002506818A5 JP2002506818A5 (cg-RX-API-DMAC7.html) 2006-01-19

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000536378A Pending JP2002506818A (ja) 1998-03-17 1998-11-20 スタチン−マトリックスメタロプロテイナーゼ阻害剤組み合わせ物

Country Status (18)

Country Link
EP (1) EP1063991A1 (cg-RX-API-DMAC7.html)
JP (1) JP2002506818A (cg-RX-API-DMAC7.html)
KR (1) KR20010041916A (cg-RX-API-DMAC7.html)
AR (1) AR018113A1 (cg-RX-API-DMAC7.html)
AU (1) AU1591699A (cg-RX-API-DMAC7.html)
BR (1) BR9815745A (cg-RX-API-DMAC7.html)
CA (1) CA2309588A1 (cg-RX-API-DMAC7.html)
CO (1) CO5070670A1 (cg-RX-API-DMAC7.html)
GT (1) GT199900039A (cg-RX-API-DMAC7.html)
HN (1) HN1999000029A (cg-RX-API-DMAC7.html)
MY (1) MY140504A (cg-RX-API-DMAC7.html)
NZ (1) NZ505994A (cg-RX-API-DMAC7.html)
PA (1) PA8469001A1 (cg-RX-API-DMAC7.html)
PE (1) PE20000348A1 (cg-RX-API-DMAC7.html)
SV (1) SV1999000026A (cg-RX-API-DMAC7.html)
UY (1) UY25436A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999047138A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA992106B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514848A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド 医薬組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US7816347B2 (en) 2004-12-15 2010-10-19 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ127198A3 (cs) * 1995-11-02 1998-12-16 Warner-Lambert Company Způsob regulace koncentrace lipidů a farmaceutická kompozice pro tento způsob
CZ294063B6 (cs) * 1996-05-17 2004-09-15 Warner-Lambert Company Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem
MXPA99001974A (es) * 1996-12-09 2002-03-27 Warner Lambert Co Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular.
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514848A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド 医薬組成物

Also Published As

Publication number Publication date
KR20010041916A (ko) 2001-05-25
BR9815745A (pt) 2000-11-14
WO1999047138A1 (en) 1999-09-23
UY25436A1 (es) 2001-10-25
PE20000348A1 (es) 2000-05-22
AR018113A1 (es) 2001-10-31
AU1591699A (en) 1999-10-11
ZA992106B (en) 1999-09-30
NZ505994A (en) 2003-10-31
CO5070670A1 (es) 2001-08-28
GT199900039A (es) 2000-09-06
CA2309588A1 (en) 1999-09-23
HN1999000029A (es) 1999-09-29
MY140504A (en) 2009-12-31
EP1063991A1 (en) 2001-01-03
SV1999000026A (es) 2000-01-18
PA8469001A1 (es) 2002-09-17

Similar Documents

Publication Publication Date Title
AU741768B2 (en) Method for treating and preventing heart failure and ventricular dilatation
US6133304A (en) ACE inhibitor-MMP inhibitor combinations
US6340709B1 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
WO2014029848A1 (en) Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
JP2002521328A (ja) アテローム性動脈硬化症病変の治療のためのacat阻害剤およびmmp阻害剤の併用投与
US20040176393A1 (en) Statin-MMP inhibitor combinations
CA2309588A1 (en) Statin-matrix metalloproteinase inhibitor combinations
US20050020607A1 (en) Statin-MMP inhibitor combinations
AU2003248291A1 (en) Statin-matrix metalloproteinase inhibitor combinations
MXPA00005034A (en) Statin-matrix metalloproteinase inhibitor combinations
MXPA00003736A (en) Ace inhibitor-mmp inhibitor combinations
EP1366765A1 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
MXPA01000780A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
MXPA99002254A (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051117

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20051117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051117

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20051214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060414

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060822